BR112013003181A2 - composto heterocíclico - Google Patents

composto heterocíclico

Info

Publication number
BR112013003181A2
BR112013003181A2 BR112013003181A BR112013003181A BR112013003181A2 BR 112013003181 A2 BR112013003181 A2 BR 112013003181A2 BR 112013003181 A BR112013003181 A BR 112013003181A BR 112013003181 A BR112013003181 A BR 112013003181A BR 112013003181 A2 BR112013003181 A2 BR 112013003181A2
Authority
BR
Brazil
Prior art keywords
inhibitory action
sym
pi3k
heterocyclic compound
production
Prior art date
Application number
BR112013003181A
Other languages
English (en)
Other versions
BR112013003181B1 (pt
BR112013003181B8 (pt
Inventor
Fumie Takahashi
Hidehiko Fukahori
Junko Maeda
Koji Kato
Shiwaru Masahiko
Sunao Imada
Toru Asano
Yoshihiro Kozuki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112013003181A2 publication Critical patent/BR112013003181A2/pt
Publication of BR112013003181B1 publication Critical patent/BR112013003181B1/pt
Publication of BR112013003181B8 publication Critical patent/BR112013003181B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

composto heterocíclico. um composto novo e excelente que é útil como um agente para a prevenção e/ou para o tratamento de reações de reijeição em transplantes de vários órgãos, doenças alérgicas, doenças autoimunes e tumor hematológico e baseado em uma ação inibidora seletiva de pi3k<sym> e/ou uma ação inibidora da produção de il-2 e/ou uma ação inibidora da proliferação de células b (incluindo uma ação inibidora de ativação). [meios para a solução] os presentes inventores investigaram um composto que possui uma ação inibidora seletiva de pi3k<sym> e/ou uma ação inibidora da produção de il-2 e/ou uma ação inibidora da proliferação de células b (incluindo uma ação inibidora de ativação) e descobriram que o composto heterocíclico da presente invenção possui uma ação inibidora seletiva de pi3k<sym> e/ou uma ação inibidora da produção de il-2 e/ou uma ação inibidora da proliferação de células b (incluindo uma ação inibidora de ativação), completando dessa maneira a presente invenção.
BR112013003181A 2010-08-10 2011-08-09 Composto heterocíclico, sua composição farmacêutica e seus uso BR112013003181B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010179418 2010-08-10
JP2010-179418 2010-08-10
PCT/JP2011/068169 WO2012020762A1 (ja) 2010-08-10 2011-08-09 へテロ環化合物

Publications (3)

Publication Number Publication Date
BR112013003181A2 true BR112013003181A2 (pt) 2016-06-07
BR112013003181B1 BR112013003181B1 (pt) 2021-03-30
BR112013003181B8 BR112013003181B8 (pt) 2024-02-06

Family

ID=45567724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003181A BR112013003181B8 (pt) 2010-08-10 2011-08-09 Composto heterocíclico, sua composição farmacêutica e seus uso

Country Status (16)

Country Link
US (1) US8912180B2 (pt)
EP (1) EP2604601B1 (pt)
JP (1) JP5765342B2 (pt)
KR (1) KR101759762B1 (pt)
CN (1) CN103025725B (pt)
AU (1) AU2011290189B9 (pt)
BR (1) BR112013003181B8 (pt)
CA (1) CA2808435C (pt)
EA (1) EA023931B1 (pt)
ES (1) ES2570177T3 (pt)
MX (1) MX346042B (pt)
PL (1) PL2604601T3 (pt)
TW (1) TWI508961B (pt)
UA (1) UA108390C2 (pt)
WO (1) WO2012020762A1 (pt)
ZA (1) ZA201300950B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012236722A1 (en) * 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN104159895A (zh) * 2012-03-07 2014-11-19 卡迪拉保健有限公司 用于治疗血脂异常及相关疾病的新化合物
CN104870017B (zh) 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
NZ748260A (en) 2013-08-30 2020-01-31 Ptc Therapeutics Inc Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
WO2016001789A1 (en) * 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN105130960B (zh) * 2015-07-31 2018-07-06 沈阳药科大学 1,3,5-三嗪类衍生物及其应用
CN106995438B (zh) * 2016-01-22 2019-09-20 中国科学院上海药物研究所 一类取代喹唑啉-4-酮类化合物及其制备方法和医药用途
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
TW202304851A (zh) * 2016-05-05 2023-02-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
JP2019519593A (ja) * 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
US20190201409A1 (en) 2016-09-19 2019-07-04 Mei Pharma, Inc. Combination therapy
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
MX2019013862A (es) 2017-05-23 2020-01-20 Mei Pharma Inc Terapia de combinacion.
CA3072476A1 (en) * 2017-08-14 2019-02-21 Mei Pharma, Inc. Combination therapy
WO2019119206A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CN109942562B (zh) * 2019-02-27 2022-02-08 江西科技师范大学 含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用
JP2022065212A (ja) * 2019-02-28 2022-04-27 国立大学法人京都大学 組織線維化による疾患の予防又は治療のための医薬
TW202134229A (zh) * 2019-11-27 2021-09-16 日商大日本住友製藥股份有限公司 環烷基尿素衍生物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020462B1 (en) 1997-07-24 2004-02-11 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
JP4709388B2 (ja) 1999-01-25 2011-06-22 全薬工業株式会社 複素環式化合物及びそれを有効成分とする抗腫瘍剤
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2001081346A2 (en) 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
JP4493503B2 (ja) 2002-10-25 2010-06-30 全薬工業株式会社 複素環式化合物及びそれを有効成分とする抗腫瘍剤
DK1741714T3 (da) 2004-03-31 2013-04-15 Zenyaku Kogyo Kk Heterocyklisk forbindelse og middel mod ondartet turmor, der indeholder denne som aktiv ingrediens
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2599879C (en) 2005-03-11 2013-07-02 Zenyaku Kogyo Kabushikikaisha Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US20070244110A1 (en) * 2006-04-14 2007-10-18 Zenyaku Kogyo Kabushiki Kaisha Treatment of prostate cancer, melanoma or hepatic cancer
GB0612630D0 (en) 2006-06-26 2006-08-02 Novartis Ag Organic compounds
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032027A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
JP2010503648A (ja) * 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性疾患の治療のためのｐｉ３ｋ及びｍｔｏｒ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−４−（アゼチジン、ピロリジン、ピペリジン、又はアゼピン）ピリミジン誘導体
WO2008032091A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032060A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090325954A1 (en) * 2006-09-14 2009-12-31 Sam Butterworth 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032072A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090270390A1 (en) * 2006-09-14 2009-10-29 Astrazeneca Pyrimidine derivatives
WO2008032077A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
BRPI0810641A2 (pt) 2007-04-12 2019-09-24 Hoffmann La Roche "compostos farmacêuticos".
US20100227858A1 (en) 2007-07-09 2010-09-09 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
PT2409975E (pt) * 2007-11-22 2015-07-27 Zenyaku Kogyo Kk Dispersões sólidas compreendendo um corpo amorfo composto por um composto antitumoral heterocíclico
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
JP2011515462A (ja) * 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
KR20110120286A (ko) * 2009-02-12 2011-11-03 아스텔라스세이야쿠 가부시키가이샤 헤테로환 유도체

Also Published As

Publication number Publication date
KR20130099933A (ko) 2013-09-06
PL2604601T3 (pl) 2016-09-30
CN103025725B (zh) 2015-09-16
KR101759762B1 (ko) 2017-07-19
EP2604601A4 (en) 2013-11-27
AU2011290189B8 (en) 2015-02-19
UA108390C2 (uk) 2015-04-27
US20130150364A1 (en) 2013-06-13
WO2012020762A1 (ja) 2012-02-16
CA2808435A1 (en) 2012-02-16
TW201211040A (en) 2012-03-16
US8912180B2 (en) 2014-12-16
AU2011290189B2 (en) 2015-01-22
EA201390198A1 (ru) 2013-11-29
CN103025725A (zh) 2013-04-03
CA2808435C (en) 2017-05-09
MX346042B (es) 2017-03-03
TWI508961B (zh) 2015-11-21
ZA201300950B (en) 2014-04-30
AU2011290189A1 (en) 2013-02-28
JPWO2012020762A1 (ja) 2013-10-28
EP2604601A1 (en) 2013-06-19
JP5765342B2 (ja) 2015-08-19
ES2570177T3 (es) 2016-05-17
BR112013003181B1 (pt) 2021-03-30
EP2604601B1 (en) 2016-02-24
MX2013001582A (es) 2013-03-18
BR112013003181B8 (pt) 2024-02-06
AU2011290189B9 (en) 2015-02-19
EA023931B1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
BR112013003181A2 (pt) composto heterocíclico
CR20150217A (es) Inhibidores de histona demetilasas
CO2017009298A2 (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
CL2017002122A1 (es) Heterociclos bicíclicos como inhibidores de fgfr4
CO2017011851A2 (es) Compuestos novedosos
BR112015022462A2 (pt) inibidores de ido
PH12017502363A1 (en) Brk inhibitory compound
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CO6440529A2 (es) Pirimidinonas como inhibidores de pi3k
BR112015032595A2 (pt) inibidores de ido
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
ECSP12012218A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
BR112017010808A2 (pt) prevenção e tratamento de infecções microbianas
UY33486A (es) Derivados de tetrahidro-pirido-pirimidina
MX2022010638A (es) Inhibidores de pde9 para el tratamiento de enfermedades perifericas.
BR112014028042A2 (pt) inibidores de nampt
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
MX2019005165A (es) Compuestos polimericos que liberan sulfuro de hidrogeno.
UY32554A (es) Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos
FI20115135A0 (fi) Mikrofibrilloidun selluloosan tulehduksia estävä vaikutus
BR112012023752A2 (pt) derivados de pirrolopirazina e seu uso como inibidores de jak e syk
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/08/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2621 DE 30/03/2021, QUANTO AO ITEM (72) NOME DO INVENTOR.